Rigosertib not checked

Traws Pharma, Inc. · ON 01910.Na

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
4 in total · 1 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Patients will receive intravenous rigosertib 1800 mg/24 hr for 3 days every 2 weeks for first 8 cycles, then every 4 weeks thereafter + best supportive care (BSC).”In the company’s words, NCT02562443 on ClinicalTrials.gov
Tested for
Myelodysplastic Syndrome (2 trials), MDS, Refractory Anemia With Excess Blasts, RAEB, Myelodysplastic Syndromes, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
Main trialPhase 3
“The study's primary objective \[in a population of patients with MDS after failure of treatment with azacitidine (AZA) or decitabine (DAC)\], is to compare the overall survival (OS) of patients in the rigosertib group vs the Physician's Choice group, in all patients and in a subgroup of patients with IPSS-R very high risk.”In the company’s words, NCT02562443 on ClinicalTrials.gov
Other names
ON 01910.Na

Other drugs for Myelodysplastic Syndrome

All 96 drugs for Myelodysplastic Syndrome

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials4

TrialPhaseCompletesWhat it tests
Phase 3Terminated 26 Jul 2020 Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA
Phase 2Completed Dec 2020 Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs
Phase 1/2Completed 8 Dec 2020 Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
Phase 2Ended not given A Phase II, Open Study to Assess Efficacy and Safety of Rigosertib in Patients with Recessive Dystrophic Epidermolysis bullosa associated Locally Advanced/Metastatic Squamous Cell Carcinoma
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026

Follow Rigosertib

Following is part of Solo: you see every change to Rigosertib the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in